



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Yong Peng
✉ 13508081615@163.com

†These authors have contributed
equally to this work and share
first authorship

RECEIVED 15 January 2024
ACCEPTED 18 January 2024
PUBLISHED 07 February 2024

CITATION
Feng Y, Yang J, Duan W, Cai Y, Liu X
and Peng Y (2024) Corrigendum:
LASSO-derived prognostic model predicts
cancer-specific survival in advanced
pancreatic ductal adenocarcinoma
over 50 years of age: a retrospective
study of SEER database research.
Front. Oncol. 14:1370998.
doi: 10.3389/fonc.2024.1370998

COPYRIGHT
© 2024 Feng, Yang, Duan, Cai, Liu and Peng.
This is an open-access article distributed under
the terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Corrigendum: LASSO-derived prognostic model predicts cancer-specific survival in advanced pancreatic ductal adenocarcinoma over 50 years of age: a retrospective study of SEER database research

Yuan Feng[†], Junjun Yang[†], Wentao Duan, Yu Cai,
Xiaohong Liu and Yong Peng*

Department of Hepatobiliary Pancreatic and Spleen Surgery, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China

KEYWORDS

advanced pancreatic ductal adenocarcinoma, nomogram, AJCC staging, risk stratification, cancer-specific survival

A Corrigendum on

[LASSO-derived prognostic model predicts cancer-specific survival in advanced pancreatic ductal adenocarcinoma over 50 years of age: a retrospective study of SEER database research.](#)

by Feng Y, Yang J, Duan W, Cai Y, Liu X and Peng Y (2024) *Front. Oncol.* 13:1336251. doi: 10.3389/fonc.2023.1336251

Text correction

In the published article, there was an error. “Nanchang” is the wrong spelling. The correct spelling should be “Nanchong.”

This correction has been applied to the Abstract, the Methodology under the External Validation section, and to the first line of [Table 1](#).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 Clinical information on patients aged ≥ 50 years with advanced pancreatic ductal adenocarcinoma.

Variable	Whole population		Training population		Validation population		P	Nanchong Central Hospital 149
	Number	%	Number	%	Number	%		
	17,621		12,333		5,288			
Age								
50-65	6,262	35.54%	4,400	35.68%	1,862	35.21%	0.83	23
65-80	8,585	48.72%	5,983	48.51%	2,602	49.21%		84
80	2,774	15.74%	1,950	15.81%	824	15.58%		42
Race								
Black	2,072	11.76%	1,472	11.94%	600	11.35%	0.91	0
White	14,135	80.22%	9,861	79.96%	4,274	80.82%		0
Other	1,414	8.02%	1,000	8.11%	414	7.83%		149
Sex								
F	8,437	47.88%	5,919	47.99%	2,518	47.62%	0.56	64
M	9,184	52.12%	6,414	52.01%	2,770	52.38%		85
AJCC Stages								
III	3,087	17.52%	2,172	17.61%	915	17.30%	0.47	43
IV	14,534	82.48%	10,161	82.39%	4,373	82.70%		106
Site								
Head	8,045	45.66%	5,632	45.67%	2,413	45.63%		59
Body	3,542	20.10%	2,500	20.27%	1,042	19.70%	0.28	18
Tail	3,605	20.46%	2,512	20.37%	1,093	20.67%		32
Others	2,429	13.78%	1,689	13.69%	740	13.99%		40
Grade ^a								
Well	1,606	9.11%	1,136	9.21%	470	8.89%	0.15	17
Bad	1,805	10.24%	1,286	10.43%	519	9.81%		23
Unknow	14,210	80.64%	9,911	80.36%	4,299	81.30%		109
CA19-9								
Positive	5,371	30.48%	3,734	30.28%	1,637	30.96%	0.63	53
Negative	12,250	69.52%	8,599	69.72%	3,651	69.04%		96
Number							0.38	
1	14,333	81.34%	10,043	81.43%	4,290	81.13%		105
>1	3,288	18.66%	2,290	18.57%	998	18.87%		44
Radiation							0.29	
Yes	1,789	10.15%	1,285	10.42%	504	9.53%		34
No	15,832	89.85%	11,048	89.58%	4,784	90.47%		115
Chemotherapy								
Yes	10,784	61.20%	7,493	60.76%	3,291	62.24%	0.36	97
No	6,837	38.80%	4,840	39.24%	1,997	37.76%		52

^aWell: Grades I and II; Bad: Grades III and IV.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.